Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eslicarbazepine acetate in diabetic neuropathic pain
NCT01129960Phase 3Terminated
- Sponsor
- BIAL
- Start
- Nov 2010
- Primary completion
- Apr 2012
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of eslicarbazepine acetate in diabetic neuropathy (4 arms), sponsored by BIAL. Primary endpoint: Change From Baseline to Endpoint in Mean Pain at 15 weeks. Started Nov 2010; status: terminated.
02
Drugs
eslicarbazepine acetate
03
Conditions
diabetic neuropathy
Beyond the preview
Go deeper on NCT01129960.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01129960.